---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-072790"
form_type: "8-K"
ticker: "RFL"
cik: "0001713863"
company_name: "Rafael Holdings, Inc."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:38:10.648570+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rafael Holdings curtails early-stage R&D, shifts to clinical-stage deals; $0.5M severance

## Summary
- Curtailed early-stage development, including pre-clinical research at Barer Institute, to reduce spending.
- Expects severance charges of approximately $0.5 million.
- As of July 31, 2022, held $63.2M in cash, cash equivalents, and marketable securities.
- Received $33M net proceeds from real estate sale on August 23, 2022.
- Will focus on acquiring, in-licensing, or investing in clinical-stage assets.

## SEC filing metadata
- accession: 0001213900-22-072790
- form_type: 8-K
- ticker: RFL
- cik: 0001713863
- company_name: Rafael Holdings, Inc.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1713863/000121390022072790/0001213900-22-072790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1713863/000121390022072790/ea168718-8k_rafaelhold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-072790
- JSON: https://secwatch.observer/filing/0001213900-22-072790.json
- Plain text: https://secwatch.observer/filing/0001213900-22-072790.txt

## Key facts
- Restructurings & Charges
  Rafael Holdings, Inc. announced a restructuring with charges of approximately $0.5 million affecting early-stage development efforts, including pre-clinical research at the Barer Institute.
  - Type: restructuring
  - Charge: approximately $0.5 million
  - Affected area: early-stage development efforts, including pre-clinical research at the Barer Institute
  source text: On November 9, 2022, the Board of Directors of Rafael Holdings, Inc. (the “Company”) resolved to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities. The Company expects to incur severance charges in the amount of approximately $0.5 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1713863/000121390022072790/0001213900-22-072790-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.